{
    "clinical_study": {
        "@rank": "55217", 
        "arm_group": [
            {
                "arm_group_label": "Deferiprone", 
                "arm_group_type": "Experimental", 
                "description": "Deferiprone 80 mg/mL oral solution will be administered twice daily for 18 months. An initial dose 5 mg/kg/day will be administered for 6 weeks. Dose will then be escalated to 10mg/kg BID and finally to 15 mg/kg BID."
            }, 
            {
                "arm_group_label": "Deferiprone matching placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A deferiprone matching placebo oral solution will be given twice daily for 18 months."
            }
        ], 
        "brief_summary": {
            "textblock": "A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of\n      18 months of treatment with deferiprone versus placebo in patients with PKAN.\n\n      This investigator-initiated trial is funded by the European Commission's Seventh Framework\n      Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON\n      consortium  (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA OOPD (Dr.\n      Elliott Vichinsky)"
        }, 
        "brief_title": "A Two-arm Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pantothenate Kinase-Associated Neurodegeneration", 
        "condition_browse": {
            "mesh_term": [
                "Pantothenate Kinase-Associated Neurodegeneration", 
                "Nerve Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Males or females 4 years of age and older at screening visit;\n\n          -  Have PKAN, confirmed by genetic testing (supporting evidence required);\n\n          -  BAD total score \u2265 3 at the screening visit;\n\n          -  Patients who have Deep Brain Stimulation (DBS) systems or baclofen pumps in place\n             will be eligible for the study, but they must have had a stable setting for at least\n             two months prior to the screening visit and stimulation parameters / pump settings\n             must remain stable for the duration of the trial:\n\n        Main Exclusion Criteria:\n\n          -  Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin <12\n             ng/mL;\n\n          -  Treatment with deferiprone in the past 12 months;\n\n          -  Previous failure of treatment with deferiprone, or previous discontinuation of\n             treatment with deferiprone due to adverse events;\n\n          -  Conditions known to contraindicate the use of deferiprone (history of agranulocytosis\n             or recurrent episodes of neutropenia);\n\n          -  A serious, unstable chronic illness not related to PKAN condition during the past 3\n             months before screening visit including but not limited to: hepatic, renal,\n             gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or\n             immunologic disease;\n\n          -  Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 times\n             upper limit of normal at screening) or abnormal creatinine levels at screening visit;\n\n          -  Disorders associated with neutropenia (ANC < 1.5 x 10E9/L) or thrombocytopenia\n             (platelet count < 50 x 10E9/L) in the 12 months preceding the initiation of the study\n             medication. Exception: for patients whose neutropenia was attributed by the treating\n             physician to episodes of infection or to drugs associated with a decline in the\n             neutrophil count and in whom the ANC has fully recovered at the screening visit;\n\n          -  History of malignancy;\n\n        Other protocol inclusion or exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741532", 
            "org_study_id": "TIRCON2012V1", 
            "secondary_id": "1R01FD004103-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Deferiprone", 
                "description": "Deferiprone oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.", 
                "intervention_name": "Deferiprone oral solution", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DFP", 
                    "Ferriprox", 
                    "L1"
                ]
            }, 
            {
                "arm_group_label": "Deferiprone matching placebo", 
                "description": "Placebo oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.", 
                "intervention_name": "Placebo oral solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Deferiprone", 
                "Vitamin B Complex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pantothenate Kinase-associated Neurodegeneration", 
            "PKAN", 
            "NBIA", 
            "Deferiprone", 
            "Ferriprox"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "EVichinsky@mail.cho.org", 
                    "last_name": "Elliott Vichinsky, MD", 
                    "phone": "510-428-3651"
                }, 
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Children's Hospital & Research Center at Oakland"
                }, 
                "investigator": {
                    "last_name": "Elliott Vichinsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.klopstock@med.uni-muenchen.de", 
                    "last_name": "Thomas Klopstock, MD", 
                    "phone": "49-89-5160-7474"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "80336"
                    }, 
                    "name": "Klinikum der Universit\u00e4t M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Thomas Klopstock, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nnardocci@istituto-besta.it", 
                    "last_name": "Nardo Nardocci, MD", 
                    "phone": "39-02-23-941"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Foundation Neurological Institute C. Besta"
                }, 
                "investigator": {
                    "last_name": "Nardo Nardocci, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patrick.chinnery@ncl.ac.uk", 
                    "last_name": "Patrick Chinnery, MD", 
                    "phone": "44 (0) 191 241 8611"
                }, 
                "facility": {
                    "address": {
                        "city": "Newcastle Upon Tyne", 
                        "country": "United Kingdom", 
                        "zip": "NE1 3BZ"
                    }, 
                    "name": "Newcastle University Institute of Human Genetics"
                }, 
                "investigator": {
                    "last_name": "Patrick Chinnery, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)", 
        "overall_official": [
            {
                "affiliation": "ApoPharma Inc.", 
                "last_name": "Fernando Tricta, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Friedrich-Baur-Institute, Department of Neurology, University of Munich Ziemssenstr", 
                "last_name": "Thomas Klopstock, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Children's Hospital & Research Center at Oakland Haematology/ Oncology, Peadiatric Rehabilitation", 
                "last_name": "Elliott Vichinsky, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The Barry-Albright Dystonia Scale (BAD) will be completed at baseline, months 6, 12 and 18 visits and will be assessed by central raters.", 
                "measure": "Change in severity of dystonia (using BAD scale) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 Months"
            }, 
            {
                "description": "Patient Global Impression of Improvement (PGI-I) will be completed at months 6, 12 and 18 visits.", 
                "measure": "Change in patient's global impression of condition's improvement (using PGI-I) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }
        ], 
        "removed_countries": {
            "country": "Poland"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741532"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MRI T2* assessments will be completed at the baseline and month 18 visits.", 
                "measure": "Change in globus pallidus iron levels (using MRI T2*) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }, 
            {
                "description": "Unified Parkinson's Disease Rating Scale (UPDRS) will be completed at the baseline, months 6, 12, and 18 visits.", 
                "measure": "Change in motor symptoms (using UPDRS) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }, 
            {
                "description": "Pediatric Quality of Life Inventory (PedsQL) will be completed at the baseline, months 6, 12 and 18 visits.", 
                "measure": "Change in quality of life (PedsQL) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }, 
            {
                "description": "Pittsburgh Sleep Quality Index (PSQI) will be completed at the baseline, months 6, 12 and 18 visits.", 
                "measure": "Change in patient's quality of sleep (using PSQI) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }, 
            {
                "description": "WeeFIM or FIM will be completed at the baseline, months 6, 12 and 18 visits.", 
                "measure": "Change in the measure of functional independence (using WeeFIM or FIM) in patients with PKAN treated with deferiprone in comparison to placebo.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 18 months"
            }, 
            {
                "description": "Safety and tolerability will be assessed based on changes in: frequency of adverse events (AEs), frequency of serious adverse events (SAEs), discontinuation due to AEs, clinical laboratory tests (including hematology and biochemistry)and ECG from baseline to month 18.", 
                "measure": "Safety and tolerability of deferiprone in patients with PKAN.", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Pharmacokinetics steady state standard parameters will be assessed in a subset of up to 24 patients over a 12 hour dosing interval using individual serum concentration-time profiles of deferiprone and its 3-O-glucuronide metabolite.", 
                "measure": "Steady state pharmacokinetics (PK) of deferiprone and its 3-O-glucuronide metabolite.", 
                "safety_issue": "No", 
                "time_frame": "12 hours at month 6 visit"
            }
        ], 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}